Adipotide

Adipotide is an experimental peptidomimetic that takes a radically different route than GLP-1 agents: instead of dampening appetite, it specifically attacks the blood vessels that supply white fat tissue and triggers targeted cell death there. Without supply, the fat depot shrinks.

Honestly and importantly up front: clinical development was stopped over kidney toxicity. This is not a harmless fat-loss compound.

Adipotide binds prohibitin, a protein unusually abundant on the blood vessels of white fat tissue. Via an attached cell-death-triggering part it specifically destroys these vessels. The fat tissue loses its blood supply and regresses.

• The adipotide vial (lyophilized powder).
• Bacteriostatic water, U-100 insulin syringes, alcohol swabs.

Use the calculator above. A 2mg vial with 2ml water gives 1mg per ml. Just add the water to the vial and let it dissolve.

Subcutaneous in the animal studies. Given the safety record, particular restraint is warranted here.

A widely noted study (Barnhart, Kolonin, 2011) showed about 11 percent weight loss in 28 days in obese monkeys, with improved insulin resistance. The catch was in the same study: changes in kidney function appeared. Exactly this kidney toxicity is why adipotide never moved beyond the experimental stage.

• Kidney toxicity (changes in proximal tubule function), the central stop reason.
• Nausea, fluid-balance changes.
• No solid human safety data.

• The kidney toxicity is real and the reason for the development stop, take it seriously.
• No established, safe dosing protocol.
• Clearly experimental, when in doubt fall back on proven alternatives (GLP-1).

Before mixing the powder is robust, normal room temperature (around 20 to 25 degrees) is fine, ideally kept in the dark. After mixing, keep in the fridge (2 to 8 degrees), do not freeze. It stays good there for at least 8 to 10 weeks with barely any loss of potency, in practice considerably longer. Swirl or shake to mix, both are fine.